Bioatla Net Worth
Bioatla Net Worth Breakdown | BCAB |
Bioatla Net Worth Analysis
Bioatla's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bioatla's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bioatla's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bioatla's net worth analysis. One common approach is to calculate Bioatla's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bioatla's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bioatla's net worth. This approach calculates the present value of Bioatla's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bioatla's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bioatla's net worth. This involves comparing Bioatla's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bioatla's net worth relative to its peers.
Enterprise Value |
|
To determine if Bioatla is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bioatla's net worth research are outlined below:
| Bioatla had very high historical volatility over the last 90 days | |
| Bioatla may become a speculative penny stock | |
| Net Loss for the year was (123.46 M) with loss before overhead, payroll, taxes, and interest of (79.35 M). | |
| Bioatla currently holds about 178.12 M in cash with (104.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from investing.com: BioAtlas SWOT analysis oncology biotech stock faces pivotal year |
Bioatla uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bioatla. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bioatla's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Bioatla's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bioatla is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bioatla backward and forwards among themselves. Bioatla's institutional investor refers to the entity that pools money to purchase Bioatla's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 512.3 K | Renaissance Technologies Corp | 2024-09-30 | 511.4 K | Norges Bank | 2024-06-30 | 488.2 K | Mccormack Advisors International | 2024-09-30 | 452.1 K | Geode Capital Management, Llc | 2024-09-30 | 405.2 K | Bank Of Montreal | 2024-06-30 | 404.2 K | Bmo Capital Markets Corp. | 2024-06-30 | 404.2 K | Goldman Sachs Group Inc | 2024-06-30 | 358.9 K | Gsa Capital Partners Llp | 2024-09-30 | 353.8 K | Soleus Capital Management, L.p. | 2024-06-30 | 3.9 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3.7 M |
Follow Bioatla's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 80.25 M.Market Cap |
|
Project Bioatla's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.03) | (1.08) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (1.03) | (1.08) | |
| Return On Equity | (1.75) | (1.66) |
When accessing Bioatla's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bioatla's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bioatla's profitability and make more informed investment decisions.
Please note, the presentation of Bioatla's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bioatla's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bioatla's management manipulating its earnings.
Evaluate Bioatla's management efficiency
Bioatla has return on total asset (ROA) of (0.5047) % which means that it has lost $0.5047 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3906) %, meaning that it created substantial loss on money invested by shareholders. Bioatla's management efficiency ratios could be used to measure how well Bioatla manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -1.08. The current year's Return On Capital Employed is expected to grow to -1.35. At present, Bioatla's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 217.8 M, whereas Non Currrent Assets Other are forecasted to decline to about 158.9 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.48 | 2.06 | |
| Tangible Book Value Per Share | 1.48 | 2.06 | |
| Enterprise Value Over EBITDA | (0.07) | (0.07) | |
| Price Book Value Ratio | 1.66 | 1.75 | |
| Enterprise Value Multiple | (0.07) | (0.07) | |
| Price Fair Value | 1.66 | 1.75 | |
| Enterprise Value | 9.8 M | 9.3 M |
Evaluating the management effectiveness of Bioatla allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Bioatla Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 2.158 | Revenue 11 M | Quarterly Revenue Growth 0.316 | Revenue Per Share 0.228 | Return On Equity (1.39) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioatla insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioatla's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioatla insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bioatla time-series forecasting models is one of many Bioatla's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bioatla's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Bioatla Earnings per Share Projection vs Actual
Bioatla Corporate Management
| Gerhard Frey | Senior Development | Profile | |
| Cathy Chang | Senior Development | Profile | |
| Christian CPA | Controller Officer | Profile | |
| Sheri Lydick | Chief Officer | Profile | |
| Philippe Martin | Chief Operations | Profile | |
| Monica Sullivan | Senior Contracts | Profile | |
| Christian Vasquez | Controller Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioatla. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. If investors know Bioatla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioatla listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Revenue Per Share 0.228 | Quarterly Revenue Growth 0.316 | Return On Assets (0.50) | Return On Equity (1.39) |
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioatla's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bioatla is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioatla's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.